Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
19 February 2015 |
Main ID: |
NCT01640496 |
Date of registration:
|
11/07/2012 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Vitamin D Treatment in Ulcerative Colitis
Vitamin D |
Scientific title:
|
Vitamin D Treatment in Ulcerative Colitis |
Date of first enrolment:
|
July 2012 |
Target sample size:
|
0 |
Recruitment status: |
Withdrawn |
URL:
|
http://clinicaltrials.gov/show/NCT01640496 |
Study type:
|
Interventional |
Study design:
|
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
|
Phase:
|
N/A
|
|
Countries of recruitment
|
United States
| | | | | | | |
Contacts
|
Name:
|
Joel Pekow, M.D. |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
University of Chicago |
| | |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Patients must be over 18 years of age
- have a diagnosis of UC as confirmed by histology.
- UC patients must have active but mild disease as confirmed by a Mayo Clinic endoscopy
score from 2-4,
- not requiring medication adjustment during the trial.
- Patients must be capable of understanding the purpose, risks and expectations of
study participation and willing to provide written informed consent.
Exclusion Criteria:
- Individuals on vitamin D or laxative therapy (except for purposes of endoscopy
preparation),
- UC patients with fulminant colitis or active C difficile or other colonic infections,
- age<18 year old,
- individuals with bleeding disorders will be excluded from the study.
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
Health Condition(s) or Problem(s) studied
|
Inflammatory Bowel Disease
|
Ulcerative Colitis
|
Intervention(s)
|
Other: Placebo
|
Drug: Vitamin D3
|
Primary Outcome(s)
|
Mucosal Permeability
[Time Frame: 8 weeks]
|
Secondary Outcome(s)
|
Mucosal tight junction protein expression
[Time Frame: 8 weeks]
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|